Document text
Principal Investigator: Julie H Coleman
Organization: CELDARA MEDICAL, LLC
Fiscal Year: 2024
Award: $162,000
Funding agency: National Institute on Aging
While the majority of biomedical scientists end up in professions outside of academia, most receive little-to-no training in preparation for this transition. Here, we seek to establish a comprehensive training program to prepare scientists for their actual careers: to meet the nation’s greatest biomedical and clinical needs. This program includes a core curriculum covering key aspects of drug development (e.g., due diligence, preclinical development, clinical unmet need, intellectual property management, regulatory path, financing, competitive intelligence, and scientific communication), experiential learning, regular, structured collaboration with biotech professionals, training in SBIR grant mechanisms and writing, engagement with multiple early-stage biotech companies, a complementary online training platform, and a formal mentoring program. This program will be focused on one of the most critical disease-challenges of the 21st century: Alzheimer’s Disease (AD) and is
named the Alzheimer’s-focused Celdara Medical High-Potential Entrepreneurs’ Fellowship (A-CHEF). Celdara Medical (CM) is an entrepreneurial biotech company that builds academic innovations into high-potential therapeutics. A-CHEF will be run by CM in collaboration with eight universities: Brown, Dartmouth, Maine Medical Center, MDI Biological Laboratory, UDel, UNH, URI, and UVM. CM currently collaborates with each of these universities through its leadership of the NIGMS-funded Regional Accelerator Hub, the DRIVEN Accelerator Hub. CM has previously run a fellowship program (Celdara fellowship) in collaboration with Dartmouth College that acts as a pilot study for A-CHEF. The Celdara fellowship provides evidence of success, as well as a basic training structure to formalize, expand, and improve upon. A-CHEF Annual Milestones: 1) Train ≥ 5 diverse scientists from the Northeast IDeA states each year in biomedical entrepreneurship / drug development; each Fellow will (annually): a) Complete A-CHEF didactic training b) Complete due diligence on ≥ 30 AD-relevant therapeutics; c) Prepare at least one AD therapeutic pitch and present to the CM and DRIVEN teams; d) Create and iterate upon an adaptive individual development plan (IDP). 2) Create a complete funding and development plan (preclinical to clinical) for ≥1 AD therapeutic. Successful completion of the aims and milestones outlined in this application will provide invaluable immersive training and career development for biomedical scientists while also expanding the AD research workforce and advancing AD therapeutic development.
Terms: <AD dementia><Academia><Active Learning><Aducanumab><Advisory Committees><Alzheimer Type Dementia><Alzheimer disease dementia><Alzheimer sclerosis><Alzheimer syndrome><Alzheimer's><Alzheimer's Disease><Alzheimer's disease therapeutic><Alzheimer's therapeutic><Alzheimers Dementia><Award><BIIB037><Biological><Biotech><Biotechnology><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 crisis><COVID-19 epidemic><COVID-19 era><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 pandemic><COVID-19 period><COVID-19 public health crisis><COVID-19 years><CV-19><Clinic><Clinical><Collaborations><Communication><Cooperative Learning><Coronavirus Infectious Disease 2019><Curriculum><Development><Development Plans><Diagnosis><Disease><Disorder><Doctor of Philosophy><Education><Educational Curriculum><Educational aspects><Entrepreneurial Skill><Entrepreneurship><Evaluation><Experiential Learning><Feedback><Fellowship><Fellowship Program><Funding><Grant><Immersion><Individual><Intellectual Property><Intelligence><Laboratories><Leadership><Learning><Maine><Medical><Medical center><Mentors><Mentorship><NIGMS><Names><National Institute of General Medical Sciences><Outcome><Patients><Persons><Ph.D.><PhD><Phase><Pilot Projects><Preparation><Primary Senile Degenerative Dementia><Process><Research><Running><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 pandemic><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SBIR><Scientist><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Small Business Innovation Research><Small Business Innovation Research Grant><Structure><Task Forces><Therapeutic><Training><Training Programs><Universities><Writing><aduhelm><advisory team><apprentice><apprenticeship><biologic><biomedical scientist><career><career development><cognitive function><college><collegiate><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus infectious disease-19><developmental><drug development><effective therapy><effective treatment><flexibility><flexible><improved><innovate><innovation><innovative><lens><lenses><lesson plans><name><named><naming><next generation><novel><operation><operations><pilot study><pre-clinical><pre-clinical development><preclinical><preclinical development><preparations><primary degenerative dementia><programs><recruit><responsible research conduct><senile dementia of the Alzheimer type><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><success><therapeutic agent development><therapeutic development>